details

Peer companies

;

Share Market News

JB Chemicals & Pharmaceuticals is currently trading at Rs. 587.45, up by 10.50 points or 1.82% from its previous closing of Rs. 576.95 on the BSE.The scrip opened at Rs. 582.85 and has touched a high and low of Rs. 591.40 and Rs. 572.90 respectively. So far 4545 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 591.40 on 11-Feb-2020 and a 52 week low of Rs. 302.80 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 591.40 and Rs. 500.00 respectively. The current market cap of the company is Rs. 4555.78 crore.The promoters holding in the company stood at 55.68%, while Institutions and Non-Institutions held 21.19% and 23.13% respectively.JB Chemicals & Pharmaceuticals has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the company`s newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli in Gujarat. The said inspection was carried out from June 24 to June 28, 2019. At the end of the inspection, ‘No Objectionable Observation’ were found and no Form 483 was issued. This new facility known as (T20) has already been approved by the other regulatory authorities like EU, TGA-Australia, Saphra-South Africa. This is an another facility in addition to one already approved by USFDA. The new facility will augment the company`s manufacturing capacity for regulated markets like USA, EU, Australia and South Africa.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

JB Chemicals & Pharmaceuticals is currently trading at Rs. 571.90, up by 10.80 points or 1.92% from its previous closing of Rs. 561.10 on the BSE.The scrip opened at Rs. 571.40 and has touched a high and low of Rs. 580.00 and Rs. 547.55 respectively. So far 10558 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 580 on 10-Feb-2020 and a 52 week low of Rs. 302.80 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 580 and Rs. 489.20 respectively. The current market cap of the company is Rs. 4453.38 crore.The promoters holding in the company stood at 55.68%, while Institutions and Non-Institutions held 21.19% and 23.13% respectively.US Food and Drug Administration (USFDA) has completed inspection at JB Chemicals & Pharmaceuticals’ solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat with one minor procedural observation.This observation does not impact continuity of the business and the company would continue its manufacturing activities in current good manufacturing practice (cGMP) compliant manner. The Company proposes to address this observation in the next 15 days. The said inspection was carried-out from February 03, 2020 to February 07, 2020. This is the 10th consecutive successful inspection for this facility.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

JB Chemicals & Pharmaceuticals is currently trading at Rs. 498.25, up by 5.20 points or 1.05% from its previous closing of Rs. 493.05 on the BSE.The scrip opened at Rs. 503.50 and has touched a high and low of Rs. 514.40 and Rs. 495.10 respectively. So far 15797 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 517.90 on 29-Jan-2020 and a 52 week low of Rs. 302.80 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 517.90 and Rs. 485.85 respectively. The current market cap of the company is Rs. 3847.88 crore.The promoters holding in the company stood at 55.68%, while Institutions and Non-Institutions held 21.19% and 23.13% respectively.JB Chemicals & Pharmaceuticals’ board has approved purchase of entire trademarks portfolio of Unique Pharmaceutical Laboratories (UPLL) at onetime consideration of Rs 8 crore. This transaction will be consummated before the end of this year. Consequently, the aforesaid licensing arrangement will stand terminated and as such, there would be no royalty payment beginning next financial year.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

The Revenue for the quarter ended  December 2019 of Rs. 3849.55 millions grew by 9.38 % from Rs. 3519.28 millions.The company has announced a 34.07% increase in its profits to Rs . 621.71  millions for the  quarter ended December 2019 compared to Rs. 463.73 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 1001.04 millions compared to 880.10 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 3849.55 3519.28 9.38 12238.79 11221.09 9.07 15011.87 12542.04 19.69 Other Income 160.22 155.79 2.84 464.66 248.66 86.87 402.25 357.86 12.40 PBIDT 1001.04 880.10 13.74 3235.67 2534.53 27.66 3282.15 2384.05 37.67 Interest 8.53 12.69 -32.78 25.31 32.57 -22.29 41.15 34.14 20.53 PBDT 992.51 867.41 14.42 3210.36 2501.96 28.31 3241.00 2349.91 37.92 Depreciation 165.46 144.85 14.23 483.98 434.16 11.48 548.25 559.48 -2.01 PBT 827.05 722.56 14.46 2726.38 2067.80 31.85 2692.75 1790.43 50.40 TAX 205.34 258.83 -20.67 553.63 668.97 -17.24 872.16 510.42 70.87 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 621.71 463.73 34.07 2172.75 1398.84 55.33 1820.59 1280.01 42.23 Equity 160.47 169.94 -5.57 160.47 169.94 -5.57 160.47 169.64 -5.41 PBIDTM(%) 26.00 25.01 3.98 26.44 22.59 17.05 21.86 19.01 15.02

The company witnessed a 5.90% growth in the revenue at Rs. 4281.24 millions for the quarter ended September 2019 as compared to Rs. 4042.74 millions during the year-ago period.Net profit surges 86.54% to Rs. 959.58  millions  from Rs. 514.40 millions in the quarter ended September 2019.Operating profit for the quarter ended September 2019 rose to 1188.71 millions as compared to 902.25 millions of corresponding quarter ended September 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201909 201809 % Var 201909 201809 % Var 201903 201803 % Var Sales 4281.24 4042.74 5.90 8389.24 7701.81 8.93 15011.87 12542.04 19.69 Other Income 181.07 81.05 123.41 304.44 92.87 227.81 402.25 357.86 12.40 PBIDT 1188.71 902.25 31.75 2234.63 1654.43 35.07 3282.15 2384.05 37.67 Interest 8.74 7.16 22.07 16.78 19.88 -15.59 41.15 34.14 20.53 PBDT 1179.97 895.09 31.83 2217.85 1634.55 35.69 3241.00 2349.91 37.92 Depreciation 162.23 144.66 12.15 318.52 289.31 10.10 548.25 559.48 -2.01 PBT 1017.74 750.43 35.62 1899.33 1345.24 41.19 2692.75 1790.43 50.40 TAX 58.16 236.03 -75.36 348.29 410.14 -15.08 872.16 510.42 70.87 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 959.58 514.40 86.54 1551.04 935.11 65.87 1820.59 1280.01 42.23 Equity 160.47 169.64 -5.41 160.47 169.64 -5.41 160.47 169.64 -5.41 PBIDTM(%) 27.77 22.32 24.41 26.64 21.48 24.00 21.86 19.01 15.02

The revenue zoomed 12.27% to Rs. 4108.00 millions for the quarter ended June 2019 as compared to Rs. 3659.07 millions during the corresponding quarter last year.Net Profit recorded in the quarter ended June 2019 rise to 40.59% to Rs. 591.46  millions  compared to R. 420.71 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 1045.92 millions from 752.18 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 4108.00 3659.07 12.27 4108.00 3659.07 12.27 15011.87 12542.04 19.69 Other Income 123.37 11.82 943.74 123.37 11.82 943.74 402.25 357.86 12.40 PBIDT 1045.92 752.18 39.05 1045.92 752.18 39.05 3282.15 2384.05 37.67 Interest 8.04 12.72 -36.79 8.04 12.72 -36.79 41.15 34.14 20.53 PBDT 1037.88 739.46 40.36 1037.88 739.46 40.36 3241.00 2349.91 37.92 Depreciation 156.29 144.65 8.05 156.29 144.65 8.05 548.25 559.48 -2.01 PBT 881.59 594.81 48.21 881.59 594.81 48.21 2692.75 1790.43 50.40 TAX 290.13 174.11 66.64 290.13 174.11 66.64 872.16 510.42 70.87 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 591.46 420.71 40.59 591.46 420.71 40.59 1820.59 1280.01 42.23 Equity 160.47 169.64 -5.41 160.47 169.64 -5.41 160.47 169.64 -5.41 PBIDTM(%) 25.46 20.56 23.86 25.46 20.56 23.86 21.86 19.01 15.02

JB Chemicals & Pharmaceuticals is currently trading at Rs. 370.85, up by 3.10 points or 0.84% from its previous closing of Rs. 367.75 on the BSE.The scrip opened at Rs. 370.30 and has touched a high and low of Rs. 372.00 and Rs. 367.90 respectively. The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 407.10 on 28-May-2019 and a 52 week low of Rs. 250.00 on 16-Jul-2018.Last one week high and low of the scrip stood at Rs. 380.00 and Rs. 361.20 respectively. The current market cap of the company is Rs. 2951.91 crore.The promoters holding in the company stood at 56.02%, while Institutions and Non-Institutions held 21.16% and 22.82% respectively.JB Chemicals & Pharmaceuticals has entered into a Memorandum of Understanding (MoU) with Greenscape Builders & Developers for assignment of company`s leasehold interest in plots of land at Navi Mumbai, subject to the terms and conditions of the MoU and subject further to execution of definitive agreements, for aggregate consideration of Rs 20.51 crore. The contemplated transaction does not fall within related party transactions.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

JB Chemicals & Pharmaceuticals is currently trading at Rs. 365.50, up by 0.95 points or 0.26% from its previous closing of Rs. 364.55 on the BSE.The scrip opened at Rs. 361.60 and has touched a high and low of Rs. 365.50 and Rs. 361.60 respectively. The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 407.10 on 28-May-2019 and a 52 week low of Rs. 236.00 on 11-Jul-2018.Last one week high and low of the scrip stood at Rs. 385.00 and Rs. 361.60 respectively. The current market cap of the company is Rs. 2932.65 crore.The promoters holding in the company stood at 56.02%, while Institutions and Non-Institutions held 21.16% and 22.82% respectively.The US Food and Drug Administration (USFDA) has concluded inspection of JB Chemicals & Pharmaceuticals’ newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat.At the end of inspection, no objectionable observations were found and hence no Form 483 was issued. The said inspection was carried out from June 24, 2019 to June 28, 2019. This facility has capacity of 2 billion tablets per annum, which is expandable to 9 billion tablets per annum.This new facility has already been approved by EU authorities in February 2019 and classified as cGMP compliant. The new facility will augment the company`s manufacturing capacity for regulated markets like USA and EU as and when the product approvals are received.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

A fair growth of 15.55% in the revenue at Rs. 3521.21 millions was reported in the December 2018 quarter as compared to Rs. 3047.42 millions during year-ago period.The company has announced a 37.00% increase in its profits to Rs . 463.74  millions for the  quarter ended December 2018 compared to Rs. 338.50 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 880.11 millions compared to 639.35 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 3521.21 3047.42 15.55 11223.67 9358.99 19.92 12547.34 11986.94 4.68 Other Income 153.87 53.20 189.23 246.09 241.61 1.85 352.55 458.90 -23.17 PBIDT 880.11 639.35 37.66 2534.54 1876.11 35.10 2384.05 2680.49 -11.06 Interest 12.69 6.11 107.69 32.57 24.63 32.24 34.14 50.01 -31.73 PBDT 867.42 633.24 36.98 2501.97 1851.48 35.13 2349.91 2630.48 -10.67 Depreciation 144.85 142.50 1.65 434.16 429.05 1.19 559.48 462.64 20.93 PBT 722.57 490.74 47.24 2067.81 1422.43 45.37 1790.43 2167.84 -17.41 TAX 258.83 152.24 70.01 668.97 363.02 84.28 510.43 438.19 16.49 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 463.74 338.50 37.00 1398.85 1059.41 32.04 1280.00 1729.65 -26.00 Equity 169.94 169.64 0.18 169.94 169.64 0.18 169.64 169.64 0.00 PBIDTM(%) 24.99 20.98 19.13 22.58 20.05 12.65 19.00 22.36 -15.03

The September 2018 quarter revenue stood at Rs. 4042.74 millions, up 16.40% as compared to Rs. 3473.19 millions during the corresponding quarter last year.Net profit declined -0.55% to Rs. 514.40 millions from Rs. 517.24 millions.Operating profit for the quarter ended September 2018 rose to 902.25 millions as compared to 833.37 millions of corresponding quarter ended September 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201803 201703 % Var Sales 4042.74 3473.19 16.40 7702.46 6311.57 22.04 12547.34 11986.94 4.68 Other Income 81.05 95.69 -15.30 92.22 188.41 -51.05 352.55 458.90 -23.17 PBIDT 902.25 833.37 8.27 1654.43 1236.76 33.77 2384.05 2680.49 -11.06 Interest 7.16 10.61 -32.52 19.88 18.52 7.34 34.14 50.01 -31.73 PBDT 895.09 822.76 8.79 1634.55 1218.24 34.17 2349.91 2630.48 -10.67 Depreciation 144.66 143.27 0.97 289.31 286.55 0.96 559.48 462.64 20.93 PBT 750.43 679.49 10.44 1345.24 931.69 44.39 1790.43 2167.84 -17.41 TAX 236.03 162.25 45.47 410.14 210.78 94.58 510.43 438.19 16.49 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 514.40 517.24 -0.55 935.11 720.91 29.71 1280.00 1729.65 -26.00 Equity 169.64 169.64 0.00 169.64 169.64 0.00 169.64 169.64 0.00 PBIDTM(%) 22.32 23.99 -6.99 21.48 19.60 9.62 19.00 22.36 -15.03

JB Chemicals & Pharmaceuticals is currently trading at Rs. 299.85, up by 1.00 points or 0.33% from its previous closing of Rs. 298.85 on the BSE.The scrip opened at Rs. 300.15 and has touched a high and low of Rs. 302.00 and Rs. 289.55 respectively. So far 14951 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 351.00 on 03-Sep-2018 and a 52 week low of Rs. 236.00 on 11-Jul-2018.Last one week high and low of the scrip stood at Rs. 304.85 and Rs. 289.55 respectively. The current market cap of the company is Rs. 2450.69 crore.The promoters holding in the company stood at 55.81%, while Institutions and Non-Institutions held 18.94% and 25.24% respectively.US Food and Drug Administration (USFDA) has issued four minor observations to JB Chemicals & Pharmaceuticals’ solid oral manufacturing facility at Panoli, Gujarat. The company proposes to address these observations within next 15 days. These observations will not have any impact on the current business and will facilitate ANDA of capsule product that is already filed.The company went through a USFDA pre-approval inspection (PAI) for ANDA filed for a capsule product. The said inspection was carried out from October 15-18, 2018 at the company`s solid oral manufacturing facility at Panoli.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

JB Chemicals & Pharmaceuticals is currently trading at Rs. 332.45, up by 2.75 points or 0.83% from its previous closing of Rs. 329.70 on the BSE.The scrip opened at Rs. 329.70 and has touched a high and low of Rs. 340.95 and Rs. 329.70 respectively. So far 57694 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 344.00 on 01-Jan-2018 and a 52 week low of Rs. 236.00 on 11-Jul-2018.Last one week high and low of the scrip stood at Rs. 340.95 and Rs. 300.00 respectively. The current market cap of the company is Rs. 2782.46 crore.The promoters holding in the company stood at 55.81%, while Institutions and Non-Institutions held 18.00% and 26.19% respectively.JB Chemicals & Pharmaceuticals’ US Food and Drug Administration (USFDA) approved solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat has successfully passed periodical inspection by USFDA with two minor procedural observations.These observations do not impact continuity of company`s business and the company would continue its manufacturing activities in cGMP compliant manner. The company proposes to address these observations in the next 30 days. The said inspection was carried out from August 20, 2018 to August 24, 2018.JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).